Delivery Order W81K0225DA010-W81K0225FA133
- Not listed
- The Defense Health Agency (DHA) awarded a $3.5 million firm fixed-price purchase order to Biofire Defense LLC on September 30, 2024, for molecular diagnostic kits with a completion date of September 29, 2029. This contract, which includes no set-aside designation, will be performed in Bethesda, Maryland. Biofire Defense is a specialized manufacturer of biological agent identification and molecular diagnostic solutions based in Salt Lake City, Utah, known for its FilmArray and RAZOR Mk II systems...
- The Defense Health Agency awarded a $828,024.90 firm fixed price delivery order to Biofire Defense LLC under an unspecified contract vehicle. The order is for respiratory panel testing services to support DHA programs. Work will be performed in Salt Lake City, Utah through December 31, 2021. The prime contractor will provide respiratory disease diagnostic panels to assist the Defense Health Agency in monitoring the health of military personnel. No subcontractors or set-aside designations were...
- Biofire Defense LLC was awarded a delivery order valued at $312,983.40 by the Bureau of Medicine and Surgery (BUMED), a component of the Department of Defense, for the procurement of respiratory panels. The contract is issued under a Multiple Award Schedule (MAS) mechanism and carries a firm fixed-price structure with no set-aside designation. Work is scheduled for completion by September 15, 2026, with the place of performance designated as Peru. Biofire Defense, a Salt Lake City-based...
- The Defense Health Agency awarded a $93,760 firm fixed-price purchase order to Biofire Defense LLC on November 15, 2023, for extended warranty and preventive maintenance services supporting four Biofire FilmArray 2.0 diagnostic units at Naval Health Clinic Lemoore, California. The five-year contract, extending through November 14, 2028, encompasses comprehensive maintenance services including preventive maintenance, recalibration, quality inspection, software upgrades, training, equipment...
- This federal contract award was made by the Bureau of Medicine and Surgery, a Defense agency, to Biofire Defense LLC, a for-profit limited liability company and manufacturer of goods. The $48,748.00 firm fixed price purchase order is for the delivery of a Respiratory Panel 2.1 IVD with 30 tests. The contract has an ultimate completion date of March 11, 2025. Biofire Defense LLC is a provider of biological agent identification products, including the Biofire FilmArray and RAZOR Mk II systems,...
- The Defense Health Agency (DOD) awarded a $742,431.36 firm fixed price purchase order to Biofire Defense LLC of Salt Lake City, Utah. The contract is to provide Respiratory Panel 2.1 In Vitro Diagnostic tests from November 7, 2022 through January 11, 2023. Biofire Defense LLC will deliver their Biofire Respiratory Panel 2.1 tests, which can rapidly detect more than twenty common respiratory pathogens including influenza A and B, respiratory syncytial virus, rhinovirus/enterovirus, coronavirus...
- This federal contract award is for the purchase of a BIOFIRE ANALYZER from Biofire Defense LLC, a for-profit limited liability company based in Salt Lake City, Utah. The $8,000.00 firm fixed-price purchase order was awarded on November 4, 2021 by the Defense Health Agency, an alternate name for the Defense Department's Defense Health Agency. The award has an ultimate completion date of January 2, 2022 and does not have a set-aside designation. Biofire Defense LLC is a manufacturer of specialized...
- The Bureau of Medicine and Surgery awarded a $18,034 firm fixed-price purchase order to Biofire Defense LLC on December 3, 2024, for the BIOFIRE DEFENSE PRODUCT NGDS-ASY-0017. The contract, which requires completion by February 28, 2025, will be performed in Frederick, Maryland. This purchase order represents a tactical procurement from Biofire Defense, a Salt Lake City-based manufacturer specializing in molecular diagnostic technologies and biological agent identification products. No set-aside...
- This firm-fixed-price purchase order was awarded to Biofire Diagnostics LLC by the Defense Health Agency to provide FDA-approved molecular diagnostic panels compatible with the BioFire Torch system. The $1,881,825.06 contract covers a base period through September 30, 2025 and includes respiratory, blood culture identification, and meningitis panels with specific pathogen targets. This requirement originated from a sources sought notice for Tripler Army Medical Center. The award does not have...
- This firm-fixed-price purchase order was awarded by the U.S. Navy's Bureau of Medicine and Surgery (BUMED) to Biofire Defense LLC, a for-profit limited liability company based in Salt Lake City, Utah. The contract is for the delivery of Biofire FilmArray 2.0 complete systems, a molecular diagnostic technology used for rapid pathogen detection and infectious disease testing. The contract has a ceiling value of $39,206.77 and a period of performance ending on April 24, 2020. This contract award is...
- W81K0225DA010Indefinite Delivery Contract
- W81K0225DA010-W81K0225FA133Delivery Order
The Defense Health Agency awarded a delivery order to Biofire Defense LLC on October 1, 2025, for an equipment lease contract valued at $968,331.59 through September 30, 2026. The contract covers the lease of two multiplex molecular analyzer systems and the supply of testing panel reagents for the Department of Pathology at Madigan Army Medical Center in Tacoma, Washington. The award employs firm fixed-price pricing and carries no set-aside designation, reflecting Biofire Defense's competitive positioning as an established federal vendor. This delivery order represents a continuation of the Defense Health Agency's reliance on Biofire Defense's advanced diagnostic capabilities to support clinical laboratory operations at a major Army medical facility. Biofire Defense LLC, a Salt Lake City-based manufacturer of biological agent identification and molecular diagnostic products, has demonstrated substantial expertise in providing federal agencies with rapid and accurate diagnostic testing technologies. The company's FilmArray and RAZOR Mk II systems, along with associated testing panels covering respiratory, gastrointestinal, and fever pathogens, have made it a critical provider across the Department of Defense, National Institutes of Health, and other federal entities. This MAMC contract exemplifies the Defense Health Agency's continued investment in advanced multiplex molecular diagnostics to enhance medical readiness and patient care capabilities within the military health system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 9/11/25 |